Skip To Main Content
Vincenzo Barnaba on Muck Rack

Vincenzo Barnaba

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vincenzo

Contact Vincenzo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CD39 as a metabolic rheostat of immunoregulation - Cellular & Molecular Immunology

|
By Vincenzo Barnaba, Silvano Sozzani
| Nature Verified
L. Zhang et al. proposed novel immunotherapeutic strategies to limit the progression of inflammatory bowel diseases by targeting the interplay between the membrane-bound CD39 molecule and cellular metabolism — specifically, by increasing regulatory T-cell function through the modulation of glucose metabolism and suppressing pathogenic proinflammatory Th17 responses via the modulation of oxidative metabolism.
Open in Who Shared Issue with article?

Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination - Nature Immunology

|
By Alba Grifoni, Silvia Marchese, Federico Forneris, Alessandro Sette, Anna Sapino, Nadia Brasu, Carlo De Intinis, Marco Macagno, Raffaele De Francesco, Vincenzo Barnaba
| Nature Verified
Abstract Understanding immune responses to SARS-CoV-2 messenger RNA (mRNA) vaccines is of great interest, principally because of the poor knowledge about the mechanisms of protection. In the present study, we analyzed longitudinally B cell and T cell memory programs against the spike (S) protein derived from ancestral SARS-CoV-2 (Wuhan-1), B.1.351 (beta), B.1.617.2 (delta) and B.1.1.529 (omicron) variants of concern (VOCs) after immunization with an mRNA-based vaccine (Pfizer).
Open in Who Shared Issue with article?
See all 2 articles